All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2004-005020-41 | Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren | 2008-06-30 | due-trials |
Completed, but no date, and reported results | 2005-004051-35 | Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients | bad-data | |
Reported results | 2005-004454-27 | Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine... | 2009-07-31 | due-trials |
Reported results | 2006-000504-17 | Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin >... | 2010-09-06 | due-trials |
Reported results | 2006-003122-28 | Argatroban versus Lepirudin in Critically Ill Patients | 2012-03-31 | due-trials |
Completed, but no date, and reported results Terminated | 2006-005296-18 | Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose HAVAS-Studie (Haemate HS in patients with severe bleeding undergoing valve replace... | bad-data | |
Reported results Terminated | 2007-000730-40 | Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC) | 2010-09-15 | due-trials |
Reported results | 2007-002659-17 | Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence. | 2013-07-09 | due-trials |
Reported results | 2013-000577-77 | EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options) | 2020-03-31 | due-trials |
Completed, but no date Terminated | 2013-004604-19 | Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheum... | bad-data | |
Other | 2017-000304-14 | Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma Phase II Studie zur Vakzinierung mit lysat-bela... | not-yet-due | |
Completed, report not yet due | 2018-002936-26 | Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma | 2024-01-08 | not-yet-due |
Completed, report not yet due | 2019-001416-30 | IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation IDH2-Post-Allo-Trial: Enasideni... | 2024-07-24 | not-yet-due |
Not reported | 2020-004695-18 | Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals Rekonvaleszenten Plasma / Camostat mesylat bei Sars-CoV-2 Q-PCR-positiven Personen mit hohem Risiko ... | 2021-10-29 | due-trials |
Other | 2022-002435-66 | Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transp... | not-yet-due |